08.01.2015 17:48:39

Infinity Halts Development Of Duvelisib For Rheumatoid Arthritis

(RTTNews) - Infinity Pharmaceuticals, Inc. (INFI) said Thursday that it will stop any further clinical development of its experimental drug duvelisib for the treatment of rheumatoid arthritis, as a mid-stage study evaluating the drug for that purpose failed to meet its main goal.

The Phase 2, double-blind, randomized, placebo-controlled study was evaluating the efficacy, safety and pharmacokinetics of duvelisib dosed at either 0.5 mg, 1.0 mg or 5.0 mg twice daily for 12 weeks with background methotrexate compared to treatment with placebo plus methotrexate.

The study, which evaluated 322 adults with active moderate-to-severe rheumatoid arthritis receiving a stable dose of methotrexate, failed to meet its primary efficacy goal of generating at least 20% improvement for a certain proportion of patients after 12 weeks of treatment, a response rate criteria set by American College of Rheumatology.

However, Cambridge, Massachusetts-based Infinity said it continues to focus on advancing duvelisib for the treatment of blood cancers such as indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, for which there are no cures.

In September, Infinity entered into a collaboration deal with AbbVie Inc (ABBV) to develop and commercialize duvelisib for the treatment of cancer. Under the deal, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones.

Infinity shares are currently trading at $15.03, down $1.30 or 7.95%. The shares trade in a 52-week range of $8.40 to $18.25.

Nachrichten zu Infinity Pharmaceuticals IncShsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Infinity Pharmaceuticals IncShsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Infinity Pharmaceuticals IncShs 0,00 0,00% Infinity Pharmaceuticals IncShs